QQ客服 官方微博 反馈留言

	Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
	Yang, Zhen-Zhou; Li, Meng-Xia; He, Hao; Ruan, Zhi-Hua; Zhu, Yu-Xi; Li, Rong-Qing; He, Xiao; Lan, Bao-Hua; Zhang, Zhi-Min; Liu, Guo-Dong
刊名	BMC CANCER
	2017
卷号	17
关键词	EGFR-TKIs Erlotinib Gefitinib NSCLC EGFR mutation
ISSN号	1471-2407
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3425043
专题	昆明医科大学
推荐引用方式 GB/T 7714	Yang, Zhen-Zhou,Li, Meng-Xia,He, Hao,et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study[J]. BMC CANCER,2017,17.
APA	Yang, Zhen-Zhou.,Li, Meng-Xia.,He, Hao.,Ruan, Zhi-Hua.,Zhu, Yu-Xi.,...&Wang, Ge.(2017).Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.BMC CANCER,17.
MLA	Yang, Zhen-Zhou,et al."Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study".BMC CANCER 17(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。